StockData
Denali Therapeutics Inc. logo

Denali Therapeutics Inc. (DNLI) stock

DNLINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30
$18.89−0.84 (-4.26%)

Close on Nov 12, 2026Market cap $3.02BP/E –Yield –

Denali Therapeutics operating margin

Operating margin is operating income as a percentage of revenue.

Denali Therapeutics's operating margin for the twelve months ending Jun 30, 2024 was -37938.0%. For fiscal 2023 it was -59.5%, against -314.2% the year before. The highest annual figure on record is 18.7% in fiscal 2020.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2023Dec 31, 2023-59.5%+254.6
FY2022Dec 31, 2022-314.2%+293.6
FY2021Dec 31, 2021-607.8%−626.5
FY2020Dec 31, 202018.7%+817.8
FY2019Dec 31, 2019-799.1%−763.2
FY2018Dec 31, 2018-35.9%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-3622.1%−2597.7
Q3 FY2023Sep 30, 2023-8981.5%−5961.3
Q2 FY2023Jun 30, 202358.0%+175.0
Q1 FY2023Mar 31, 2023-343.8%−186.0
Q4 FY2022Dec 31, 2022-1024.4%−408.2
Q3 FY2022Sep 30, 2022-3020.1%−1400.6
Q2 FY2022Jun 30, 2022-117.0%+152.5
Q1 FY2022Mar 31, 2022-157.8%+741.1
Q4 FY2021Dec 31, 2021-616.3%−693.3
Q3 FY2021Sep 30, 2021-1619.5%−979.5
Q2 FY2021Jun 30, 2021-269.5%+778.5
Q1 FY2021Mar 31, 2021-898.9%+765.0
Q4 FY2020Dec 31, 202077.0%+1313.3
Q3 FY2020Sep 30, 2020-640.0%−271.3
Q2 FY2020Jun 30, 2020-1048.0%+447.4
Q1 FY2020Mar 31, 2020-1663.9%−653.0
Q4 FY2019Dec 31, 2019-1236.3%−1295.7
Q3 FY2019Sep 30, 2019-368.7%+2808.2
Q2 FY2019Jun 30, 2019-1495.4%+1986.5
Q1 FY2019Mar 31, 2019-1010.9%+3006.0
Q4 FY2018Dec 31, 201859.5%–
Q3 FY2018Sep 30, 2018-3176.9%–
Q2 FY2018Jun 30, 2018-3481.9%–
Q1 FY2018Mar 31, 2018-4016.8%–

More Denali Therapeutics figures

See a number that looks wrong?